Evelo Biosciences, which is developing microbial therapies that act on the gut to treat inflammatory diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The Cambridge, MA-based company was founded in 2014 and plans to list on the Nasdaq under the symbol EVLO. Evelo Biosciences filed confidentially on March 5, 2018. Morgan Stanley, Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
